Dynogen to go public in reverse merger with Apex; withdrawn
Private biotech Dynogen (GI and uro/gyn treatments) has agreed to merge with Apex Bioventures, a special purpose acquisition company, and take on its public status.
- Specialty Pharmaceuticals
- Includes Contract
- Reverse Acquisition
- Special Purpose Acquisition
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.